UCB Makes Another Push To Get Bimzelx Over Finishing Line In US
Potential Blockbuster Resubmitted For Psoriasis
Executive Summary
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.
You may also be interested in...
UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
Sanofi Makes Big Strides In Eradicating Sleeping Sickness
The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.
AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.